[{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ National Institutes of Health"},{"orgOrder":0,"company":"Synairgen","sponsor":"University of Southampton","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ University of Southampton","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ University of Southampton"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Akron Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Synairgen"},{"orgOrder":0,"company":"Synairgen","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Synairgen"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Aerogen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Aerogen"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Parexel Biotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Synairgen"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Synairgen
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
